Alteplase + Defibrotide SodiumContraindicated
DEFITELIO may enhance the pharmacodynamic activity of alteplase, increasing risk of hemorrhage. Concomitant use is contraindicated.
Source: NLP:defibrotide sodium
Alteplase Interactions
Brand names: Cathflo Activase
Route: Intravenous
Contraindications
CONTRAINDICATIONS Cathflo Activase should not be administered to patients with known hypersensitivity to Alteplase or any component of the formulation (see DESCRIPTION ).
Pregnancy & Breastfeeding
Pregnancy Alteplase has been shown to have an embryocidal effect due to an increased postimplantation loss rate in rabbits when administered intravenously during organogenesis at a dose (3 mg/kg) approximately 50 times human exposure (based on AUC) at the dose for restoration of function to occluded CVADs. No maternal or fetal toxicity was evident at a dose (1 mg/kg) approximately 16 times human exposure at the dose for restoration of function to occluded CVADs. There are no adequate and well‑controlled studies in pregnant women. Cathflo Activase should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
6 interactions on record
Antiplatelet drugs increase the risk of bleeding if administered prior to, during, or after Alteplase therapy.
Source: NLP:alteplase
Intravenous nitroglycerin decreases the thrombolytic effect of alteplase; caution advised with sublingual nitroglycerin during alteplase therapy.
Source: NLP:nitroglycerin
Anticoagulants increase the risk of bleeding if administered prior to, during, or after Alteplase therapy.
Source: NLP:alteplase
Concomitant therapy may decrease the efficacy of both tranexamic acid and tissue plasminogen activators. Discontinue tranexamic acid if patient requires tissue plasminogen activators.
Source: NLP:tranexamic acid
Alteplase + Angiotensin IiModerate
Concomitant angiotensin-converting enzyme inhibitors may increase the risk of angioedema, particularly in patients with acute ischemic stroke.
Source: NLP:alteplase